Otsuka Pakistan Ltd. (OTSU) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

With a growth in Net Profit of NAN%, the company declared Very Positive results in Mar 25

The company has declared positive results for the last 2 consecutive quarters
OPERATING CASH FLOW(Y) Highest at PKR 404.73 MM
NET PROFIT(Q) At PKR 12.59 MM has Grown at 1,129.49%
PRE-TAX PROFIT(Q) At PKR 27.24 has Grown at 166.81%

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

PKR 4,195 Million (Small Cap)

P/E

140.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.72

Return on Equity

32.78%

Price to Book

5.14

Revenue and Profits:

Net Sales:

885 Million

(Quarterly Results - Mar 2025)

Net Profit:

13 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

98.68%

6 Months

84.19%

1 Year

211.28%

2 Years

396.78%

3 Years

64.32%

4 Years

26.77%

5 Years

18.78%

Otsuka Pakistan Ltd. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

11.91%

EBIT Growth (5y)

1.73%

EBIT to Interest (avg)

21.96

Debt to EBITDA (avg)

3.52

Net Debt to Equity (avg)

0.96

Sales to Capital Employed (avg)

1.93

Tax Ratio

60.62%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

20.36%

ROE (avg)

29.96%

Valuation key factors

Factor

Value

P/E Ratio

140

Industry P/E

Price to Book Value

5.56

EV to EBIT

30.47

EV to EBITDA

19.63

EV to Capital Employed

3.27

EV to Sales

1.21

PEG Ratio

0.21

Dividend Yield

ROCE (Latest)

10.72%

ROE (Latest)

3.98%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Bullish

Dow Theory

Mildly Bullish

No Trend

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2025 is -9.05% vs 21.52% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2025 is -92.43% vs 239.10% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "884.80",
          "val2": "972.80",
          "chgp": "-9.05%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "71.90",
          "val2": "112.00",
          "chgp": "-35.80%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.00",
          "val2": "1.10",
          "chgp": "-9.09%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "12.60",
          "val2": "166.50",
          "chgp": "-92.43%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "55.90%",
          "val2": "97.60%",
          "chgp": "-4.17%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Jun'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Jun 2024 is 3.68% vs 6.99% in Jun 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Jun 2024 is 33.33% vs -103.11% in Jun 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'24",
        "Jun'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "3,163.20",
          "val2": "3,050.90",
          "chgp": "3.68%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "93.00",
          "val2": "260.30",
          "chgp": "-64.27%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "106.20",
          "val2": "64.40",
          "chgp": "64.91%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-4.80",
          "val2": "-7.20",
          "chgp": "33.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-2.40%",
          "val2": "53.00%",
          "chgp": "-5.54%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ

Mar'25

Dec'24

Change(%)

Net Sales

884.80

972.80

-9.05%

Operating Profit (PBDIT) excl Other Income

71.90

112.00

-35.80%

Interest

1.00

1.10

-9.09%

Exceptional Items

0.00

Consolidate Net Profit

12.60

166.50

-92.43%

Operating Profit Margin (Excl OI)

55.90%

97.60%

-4.17%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Mar 2025 is -9.05% vs 21.52% in Dec 2024

Consolidated Net Profit

QoQ Growth in quarter ended Mar 2025 is -92.43% vs 239.10% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Jun'24

Jun'24

Jun'23

Change(%)

Net Sales

3,163.20

3,050.90

3.68%

Operating Profit (PBDIT) excl Other Income

93.00

260.30

-64.27%

Interest

106.20

64.40

64.91%

Exceptional Items

0.00

Consolidate Net Profit

-4.80

-7.20

33.33%

Operating Profit Margin (Excl OI)

-2.40%

53.00%

-5.54%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Jun 2024 is 3.68% vs 6.99% in Jun 2023

Consolidated Net Profit

YoY Growth in year ended Jun 2024 is 33.33% vs -103.11% in Jun 2023

All Annual Results

Company CV

About Otsuka Pakistan Ltd.

Otsuka Pakistan Ltd.

Pharmaceuticals & Biotechnology

Otsuka Pakistan Limited (OPL) is engaged in the manufacturing, marketing and distribution of intravenous (IV) infusions and trading in pharmaceutical products, nutritional foods and medical equipment. The Company's activities are focused on the manufacturing of IV Solutions and marketing them. The Company provides international solutions and medicines to doctors, hospitals and pharmacies. The Company's products include intravenous solutions, cardiac stents, clinical nutrition and therapeutic drugs. Its intravenous solutions include electrolyte solutions, standard solutions, ampoules and others. The Company offers various cardiac stents, such as firebird, jive, mustang and tango. The clinical nutrition products include aminoleban oral, aminovel 600, pan-amin g, pan-amin sg and aminoleban injection. Pletaal is the therapeutic drug of the Company. The Company's subsidiary is Messrs Otsuka Pharmaceutical Company Limited.

Company Coordinates

Company Details

30-B, S.M.C.H. Society, Off: Shahrah-e-Faisal KARACHI None : 74400

Tel: 92 21 34528651

https://www.otsuka.pk/

Registrar Details